News-Medical.Net on MSN30m
Proteins identified as key players in immunotherapy resistance for colorectal cancerA discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer.
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback